PA
RVNC

Procyon Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Procyon Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,900
Closed -$46K – 1106
2020
Q2 		$46K Buy
1,900
+200
+12% +$3.95K 0.02% 398
2020
Q1 		$25K Hold
1,700
– – 0.02% 442
2019
Q4 		$28K Buy
+1,700
New +$26.4K 0.02% 442

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Procyon Advisors's RVNC Position: Q3 2020 in Review

Procyon Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2020, closing a stake of 1,900 shares — an estimated $46K sold.

Procyon Advisors first reported a position in RVNC in Q4 2019 and held it in 3 quarters. The position peaked at $46K in Q2 2020. 153 funds tracked by Wall St. Rank hold RVNC as of Q3 2020.

  • Procyon Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Procyon Advisors sold 1,900 Revance Therapeutics, Inc. shares in Q3 2020, an estimated $46K.
  • Procyon Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 3 quarters.
  • Procyon Advisors's Revance Therapeutics, Inc. position peaked at $46K in Q2 2020.
  • 153 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.